Originally dba as ApeX Therapeutics Inc, in the Fall 2016 the firm was renamed Spun off from research done at Indiana Universityâs School of Medicine. the firm is a biotechnology company focused on the discovery, development, and commercialization of novel pharmaceuticals for the treatment of cancer and age-related macular degeneration. ApeX's drug development platform is based on exploiting the APE1/Ref-1 redox signaling and DNA repair protein in order to block multiple key survival mechanisms of cancer, all with a single new drug. ApeX Therapeutics has leveraged this deep scientific expertise to discover molecules that specifically target and inhibit the APE1/Ref-1 redox signaling and DNA repair protein pathway. Inhibitors of the Ref-1 have been shown to broadly affect several transcription factors involved in cancer cell signaling and survival, and ApeX Therapeuticsâ lead APE1/Ref-1 inhibitor, APX3330, is representative of this novel class of compounds, having shown dramatic efficacy against pre-clinical models of pancreatic cancer. The preliminary testing of human safety and non-cancer efficacy of APX3330 was established by Eisai pharmaceuticals in a previously conducted development program targeting chronic liver disease, where the compound was safely administered across a variety of doses. In Summer 2017, Apexian licensed key IP from Indiana University Research & Technology Corporation that will allow the company to develop and commercialize its lead candidate in development for cance
